Treatment of Non-ischemic Cardiomyopathies by Intravenous Extracellular Vesicles of Cardiovascular Progenitor Cells - Trial NCT05774509
Access comprehensive clinical trial information for NCT05774509 through Pure Global AI's free database. This Phase 1 trial is sponsored by Assistance Publique - Hôpitaux de Paris and is currently Not yet recruiting. The study focuses on Heart Failure With Reduced Ejection Fraction. Target enrollment is 12 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Extracellular vesicle-enriched secretome of cardiovascular progenitor cells differentiated from induced pluripotent stem cells
Interventional
biological
Sponsor & Location
Assistance Publique - Hôpitaux de Paris
Timeline & Enrollment
Phase 1
Mar 15, 2023
May 31, 2026
Primary Outcome
Serious Adverse Events
Summary
The goal of this clinical trial is to assess the safety and efficacy of three intravenous
 injections of the extracellulat vesicle-enriched secretome of cardiovascular progenitor cells
 in severely symptomatic patients with drug-refractory left ventricular (LV) dysfunction
 secondary to non-ischemic dilated cardiomyopathy. The main questions it aims to answer are:
 
 - Are these repeated injections safe and well tolerated?
 
 - Do they improve cardiac function and, if yes, to what extent?
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05774509
Non-Device Trial